A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants
Status:
Completed
Trial end date:
2022-07-12
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to learn about the safety, effects, and tolerability of
the study medicine (sisunatovir).
This study is looking for healthy adult participants who meet the following criteria:
1. Males age 18 to 55 years
2. All fertile participants must agree to the use of highly effective contraception
3. Body mass index (BMI) of 18 to 32.0 kg/m2; body weight of 55.0 to 100.0 kg.
4. Participants who are overtly healthy as determined by medical evaluation. This includes
medical history, physical examination, blood pressure, pulse rate, standard 12-lead ECG
(electrocardiogram), and laboratory tests.
This study will enroll up to 10 participants. All study participants will receive 1 dose of
sisunatovir by mouth. The study duration is expected to be about 9 weeks. This includes a
28-day screening period, 16-day inpatient stay, and 2 overnight follow-up visits, if needed.